Olanzapine is a widely used atypical antipsychotic drug (AAPD) with proven efficacy in treating schizophrenia and bipolar disorder. However, it is also associated with the highest risk of metabolic disturbances among antipsychotic medications. Long-term use can significantly increase patients’ blood glucose and lipid levels, leading to adverse effects such as hypertension, diabetes, and obesity. There are multiple strategies to manage antipsychotic-induced obesity. In recent years, significant progress has been made in both clinical and basic research on the use of traditional Chinese medicine (TCM) to treat olanzapine-induced glucose and lipid metabolic disorders. Qi and blood disharmony is identified as the primary pathophysiological mechanism underlying olanzapine-induced drug-induced obesity and metabolic disturbances. Certain TCM monotherapies, herbal compound prescriptions, or acupuncture treatments used for managing obesity and regulating glucose and lipid metabolism have shown varying degrees of efficacy in counteracting olanzapine-induced glucose and lipid metabolic disturbances. This article summarizes the recent research findings on the use of TCM to antagonize olanzapine-induced drug-induced glucose and lipid metabolic disorders and obesity, aiming to provide a reference for the clinical application of treatments for olanzapine-induced metabolic disturbances and the development of new therapeutic agents.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |